Introduction
Cartilage wear is a common and challenging problem. Because cartilage has no direct blood supply, it recovers poorly once damaged. Alongside physiotherapy and pain management, a number of biologically active options are now available that aim to support the joint itself. Patients often ask how these compare — particularly the ChondroFiller injection, the Liquid Cartilage surgical protocol, and standalone stem cell therapy. The three approaches are meaningfully different, and matching the right one to your joint requires careful assessment.
Why Advanced Options Are of Interest
Conventional measures such as analgesics and physiotherapy mainly address symptoms. Options that aim to support or restore the cartilage surface are therefore of interest, particularly for active individuals with focal defects that are unlikely to improve with conservative care alone. No approach is a cure for arthritis, and benefits vary between patients; realistic expectations are essential throughout.
What Is the ChondroFiller Injection?
ChondroFiller is a type I collagen hydrogel scaffold and a Class III CE-marked medical device, made by Meidrix Biomedicals in Germany. When delivered as an ultrasound-guided outpatient injection, it forms a gel within the joint in approximately three to five minutes, settling over the worn cartilage surface to provide a supportive collagen layer. The scaffold is acellular — it contains no cells of its own — but recruits the patient's own progenitor cells to migrate in and progressively remodel the matrix.
As a non-surgical, single-session procedure, the ChondroFiller injection does not require a theatre, incision, or general anaesthetic. It is particularly suited to accessible lesions and smaller joints, including the knee, ankle, hip, and thumb. It should be understood as a supportive, joint-preserving intervention rather than a reversal of arthritis; clinical experience indicates that benefits are meaningful but individual.
Published biomechanical studies, including Weizel et al. (2020, Acta Biomaterialia), have characterised the mechanical behaviour of collagen hydrogels such as ChondroFiller. Clinical series have also described its use in trapeziometacarpal osteoarthritis (Corain et al., 2023, Cartilage), among other joints.
What Is the Liquid Cartilage Surgical Protocol?
Liquid Cartilage is not an injection and is not a synonym for ChondroFiller. It is the Lee Liquid Cartilage Protocol (LLC Protocol) — a keyhole surgical technique developed by Professor Paul Y. F. Lee. The protocol uses the ChondroFiller scaffold as its principal component, but combines it with biological adjuncts and structured perioperative support to create a more comprehensive regenerative environment than the scaffold alone can provide.
The procedure is performed arthroscopically under anaesthetic. The defect is prepared to create a stable rim; a dry CO₂ field is established to allow the scaffold to gel correctly; platelet-rich fibrin (PRF) is applied as a biological primer; and ChondroFiller is then injected into the prepared defect. Once gelation is complete, platelet-rich plasma (PRP) and tranexamic acid are introduced to reinforce scaffold anchorage and limit bleeding. A structured rehabilitation programme follows, with protected weight-bearing for the first weeks.
Where the defect or patient profile warrants it, the surgeon may optionally introduce the patient's own mesenchymal stem cells (MSCs) — sourced from bone-marrow aspirate concentrate (BMAC) or micro-fragmented adipose tissue (mFAT) — at the time of surgery. These are applied directly to the primed defect surface before the scaffold is placed, with the aim of enhancing the regenerative signalling environment. MSC use within Liquid Cartilage is therefore a surgical adjunct to the scaffold, not a separate standalone therapy.
Liquid Cartilage is intended for larger or load-bearing defects, including those in the knee, hip, shoulder, and ankle, where the controlled surgical environment and biological augmentation are expected to improve the quality and durability of repair. Recovery is genuine surgical recovery, typically measured in weeks to months.
Free non-medical discussion
Not sure what to do next?
Information only · No medical advice or diagnosis.
What Is Standalone Stem Cell Therapy?
Stem cell therapy as a standalone approach uses the body's own MSCs — most commonly harvested from bone marrow or fat tissue — which are prepared and then introduced into the joint, typically by injection. Because it involves harvesting and processing cells, it is more involved than a simple injection and techniques vary between clinics.
Evidence suggests that intra-articular MSC injection can reduce pain and improve function in osteoarthritis and focal cartilage defects, though results depend on the source of cells, the concentration achieved, the condition of the joint, and the technique used. Standalone stem cell injection does not incorporate a structural scaffold; it relies primarily on the paracrine and immunomodulatory effects of the delivered cells rather than providing a physical matrix for cartilage in-growth.
Standalone stem cell therapy is therefore distinct both from the ChondroFiller injection (which provides a scaffold without harvested cells) and from the Liquid Cartilage surgical protocol (which combines a scaffold with optional MSCs within a controlled keyhole surgical environment).
Key Differences at a Glance
- ChondroFiller injection: non-surgical, ultrasound-guided outpatient procedure; CE-marked collagen scaffold; no cells harvested; suited to accessible and smaller defects.
- Liquid Cartilage (LLC Protocol): keyhole surgery under anaesthetic; ChondroFiller scaffold plus biological adjuncts (PRF, PRP, tranexamic acid) and optional MSCs; developed by Professor Paul Y. F. Lee; suited to larger or load-bearing defects; structured rehabilitation required.
- Standalone stem cell injection: harvested MSCs (BMAC or adipose) delivered by injection; no structural scaffold; more involved than a simple injection; technique and outcomes vary between providers.
The three approaches are not interchangeable. Selecting the right option depends on the joint involved, the size and depth of the defect, the degree of surrounding wear, the patient's activity level and goals, and whether a surgical or non-surgical pathway is appropriate.
The Value of Expert Assessment
Each of these options requires careful individual evaluation before it can be recommended. Factors such as joint alignment, the condition of the subchondral bone, the patient's age, and prior treatment history all influence suitability. Very advanced arthritis may be better managed in other ways, such as joint replacement. A specialist assessment sets realistic expectations and ensures that the chosen approach is appropriate for the specific joint and clinical picture.
Conclusion
ChondroFiller injection, the Liquid Cartilage surgical protocol, and standalone stem cell therapy each address cartilage wear from a different starting point. ChondroFiller injection offers a non-surgical, single-session collagen scaffold. Liquid Cartilage combines that scaffold with biologics and optional MSCs within a keyhole surgical technique. Standalone stem cell injection delivers harvested cells without a structural scaffold. The best choice is determined by individual assessment, not by a general preference for one approach over another.
At the London Cartilage Clinic (Harley Street), Professor Paul Y. F. Lee and the clinical team provide comprehensive, individual evaluation of cartilage and joint conditions, including guidance on which of these pathways — if any — may be appropriate. To arrange an assessment, please contact the clinic.
References
- Weizel, A., Distler, T., Schneidereit, D., & Friedrich, O. (2020). Complex mechanical behavior of human articular cartilage and hydrogels for cartilage repair. Acta Biomaterialia.
- Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.
Frequently Asked Questions
- No. ChondroFiller is the CE-marked collagen scaffold material. The ChondroFiller injection is a non-surgical, ultrasound-guided outpatient procedure that delivers the scaffold without surgery. Liquid Cartilage (the Lee Liquid Cartilage Protocol) is a keyhole surgical technique that uses the ChondroFiller scaffold together with biological adjuncts — platelet-rich fibrin, platelet-rich plasma, and optionally the patient's own stem cells — in a controlled arthroscopic environment. They are distinct approaches for different clinical situations.
- In the Liquid Cartilage surgical protocol, mesenchymal stem cells (from bone marrow or fat) may be used as an optional adjunct: they are applied to the prepared defect before the scaffold is placed, to enhance regenerative signalling during repair. This is different from standalone stem cell therapy, where harvested MSCs are injected into the joint without a structural scaffold. The ChondroFiller injection contains no harvested cells; it works by recruiting the patient's own progenitor cells from surrounding tissue into the gel matrix.
- No. Suitability depends on the joint, the size and depth of the cartilage defect, the degree of arthritis, joint alignment, and individual patient factors. Very advanced arthritis may be better managed with other interventions. A thorough specialist assessment is required before recommending any of these approaches.
- Physiotherapy and analgesics primarily manage symptoms. Approaches such as the ChondroFiller injection and the Liquid Cartilage surgical protocol aim to provide a regenerative environment at the cartilage surface, while standalone stem cell injection aims to influence the biological milieu of the joint. None is a cure for arthritis, and none reverses advanced joint degeneration. The aim is to support the joint and, where possible, reduce pain and improve function in a way that conventional symptom management cannot.
- That question cannot be answered without a detailed assessment. The clinician will review the affected joint, imaging, the extent of cartilage damage, your activity level and goals, and your overall health before advising. In some cases, more than one approach may be considered sequentially. The starting point is always an accurate diagnosis and an honest conversation about what is achievable.
London Cartilage Clinic
Ready to explore your options?
Our consultant-led team specialises in cartilage repair, regeneration and replacement — tailored to your diagnosis and long-term goals.
Legal & Medical Disclaimer
This article is written by an independent contributor and reflects their own views and experience, not necessarily those of London Cartilage Clinic. It is provided for general information and education only and does not constitute medical advice, diagnosis, or treatment.
Always seek personalised advice from a qualified healthcare professional before making decisions about your health. London Cartilage Clinic accepts no responsibility for errors, omissions, third-party content, or any loss, damage, or injury arising from reliance on this material.
If you believe this article contains inaccurate or infringing content, please contact us at [email protected].
